Effect of evolocumab early use after PCI on blood lipids and inflammatory factors in patients with ultra-high-risk ASCVD
10.3969/j.issn.1671-8348.2025.02.027
- VernacularTitle:超高危ASCVD患者PCI术后早期应用依洛尤单抗对血脂及炎症细胞因子的影响
- Author:
Weijian ZHANG
1
;
Bingkun LIU
;
Yichen LIU
;
Yao YAN
;
Chuanyan ZHAO
Author Information
1. 潍坊市益都中心医院心内科二病区,山东潍坊 262500
- Keywords:
evolocumab;
atherosclerotic cardiovascular disease;
low density lipoprotein-cholesterol;
blood lipids;
inflammatory cytokines
- From:
Chongqing Medicine
2025;54(2):446-451
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of evolocumab in the early postoperative period after percutaneous coronary intervention(PCI)on blood lipids and inflammatory cytokines in the patients with ul-tra-high-risk atherosclerotic cardiovascular disease(ASCVD).Methods A total of 65 patients with ultra-high-risk ASCVD treated by PCI in this hospital from October 2022 to March 2023 were selected as the study subjects and divided into the observation group(n=33)and control group(n=32)according to the used drugs.The patients in the control group received the treatment of oral rosuvastatin 10 mg;on the basis of the treatment in the control group,the observation group was treated with subcutaneous injection of evolocumab 140 mg immediately after PCI.The fasting blood samples were collected before surgery,on postoperative 3 d,1,3,6 months,and the levels of inflammation and blood lipid indexes were detected and recorded.The occur-rences of cardiovascular adverse events(MACE)and other complications in postoperative 6 months were re-corded.Results The levels of LDL-C,Lp-PLA2 and lipoprotein a on postoperative 3 d,1,3,6 months in the observation group were gradually decreased,moreover were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of IL-6,homocysteine and hs-CRP on postoper-ative 3 d,1,3,6 months in the two groups were decreased,moreover the levels of various indexes in the obser-vation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The incidence rate of MACE in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05);the difference in the incidence rates of other complications between the two groups was not statistically significant(P>0.05).According to the Log Rank test,the sur-vival rate of the observation group was higher than that of the control group,and the difference was statistical-ly significant(P<0.05).Conclusion The early application of evolocumab after PCI could reduce the blood lipid level and inflammatory cytokines levels of the patients with ultra-high-risk ASCVD,and increase their survival rate.
